Literature DB >> 24307584

A versatile RNA vector for delivery of coding and noncoding RNAs.

Sonja Schmid1, Lum C Zony, Benjamin R tenOever.   

Abstract

The discovery that RNA viruses, lacking any DNA intermediate, can be engineered to express both coding and noncoding RNAs suggests that this platform may have therapeutic value as a delivery vehicle. Here we illustrate that a self-replicating, noninfectious RNA, modeled on influenza virus, provides one such example of a versatile in vivo delivery system for silencing and/or expressing a desired RNA for therapeutic purposes.

Entities:  

Mesh：

Year:  2013        PMID： 24307584      PMCID： PMC3911536          DOI： 10.1128/JVI.03267-13

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  33 in total

1.  Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells.

Authors:  Yan Zeng; Eric J Wagner; Bryan R Cullen
Journal:  Mol Cell       Date:  2002-06       Impact factor: 17.970

Review 2.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

3.  The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing.

Authors:  Eugene V Makeyev; Jiangwen Zhang; Monica A Carrasco; Tom Maniatis
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

4.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.

Authors:  Dirk Grimm; Konrad L Streetz; Catherine L Jopling; Theresa A Storm; Kusum Pandey; Corrine R Davis; Patricia Marion; Felix Salazar; Mark A Kay
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

5.  Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions.

Authors:  Glenn A Marsh; Raheleh Hatami; Peter Palese
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

6.  Engineering microRNA responsiveness to decrease virus pathogenicity.

Authors:  Elizabeth J Kelly; Elizabeth M Hadac; Suzanne Greiner; Stephen J Russell
Journal:  Nat Med       Date:  2008-10-26       Impact factor: 53.440

7.  An in vivo RNAi screening approach to identify host determinants of virus replication.

Authors:  Andrew Varble; Asiel A Benitez; Sonja Schmid; David Sachs; Jaehee V Shim; Ruth Rodriguez-Barrueco; Maryline Panis; Marshall Crumiller; Jose M Silva; Ravi Sachidanandam; Benjamin R tenOever
Journal:  Cell Host Microbe       Date:  2013-09-11       Impact factor: 21.023

8.  A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication.

Authors:  Robert E Edge; Theresa J Falls; Christopher W Brown; Brian D Lichty; Harold Atkins; John C Bell
Journal:  Mol Ther       Date:  2008-06-17       Impact factor: 11.454

9.  MicroRNA-mediated species-specific attenuation of influenza A virus.

Authors:  Jasmine T Perez; Alissa M Pham; Maria H Lorini; Mark A Chua; John Steel; Benjamin R tenOever
Journal:  Nat Biotechnol       Date:  2009-05-31       Impact factor: 54.908

10.  Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines.

Authors:  Dwight Barnes; Mark Kunitomi; Marco Vignuzzi; Kalle Saksela; Raul Andino
Journal:  Cell Host Microbe       Date:  2008-09-11       Impact factor: 21.023
View more
  9 in total

1.  The Mammalian response to virus infection is independent of small RNA silencing.

Authors:  Simone Backes; Ryan A Langlois; Sonja Schmid; Andrew Varble; Jaehee V Shim; David Sachs; Benjamin R tenOever
Journal:  Cell Rep       Date:  2014-06-19       Impact factor: 9.423

Review 2.  Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals?

Authors:  Nigel J Dimmock; Andrew J Easton
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

3.  Generation of a safe and effective live viral vaccine by virus self-attenuation using species-specific artificial microRNA.

Authors:  Junwei Li; Maria T Arévalo; Diana Diaz-Arévalo; Yanping Chen; Jang-Gi Choi; Mingtao Zeng
Journal:  J Control Release       Date:  2015-04-07       Impact factor: 9.776

4.  Production of functional small interfering RNAs by an amino-terminal deletion mutant of human Dicer.

Authors:  Edward M Kennedy; Adam W Whisnant; Anand V R Kornepati; Joy B Marshall; Hal P Bogerd; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

5.  In Vivo RNAi Screening Identifies MDA5 as a Significant Contributor to the Cellular Defense against Influenza A Virus.

Authors:  Asiel A Benitez; Maryline Panis; Jia Xue; Andrew Varble; Jaehee V Shim; Amy L Frick; Carolina B López; David Sachs; Benjamin R tenOever
Journal:  Cell Rep       Date:  2015-06-11       Impact factor: 9.423

6.  A new self-attenuated therapeutic influenza vaccine that uses host cell-restricted attenuation by artificial microRNAs.

Authors:  Ke Wen; Haiyan Wang; Yanping Chen; Huixiao Yang; Zhichao Zheng; Yongyong Yan; Adilene Realivazquez Pena; Mingtao Zeng
Journal:  Int J Pharm       Date:  2021-12-06       Impact factor: 5.875

Review 7.  Development and applications of single-cycle infectious influenza A virus (sciIAV).

Authors:  Aitor Nogales; Steven F Baker; William Domm; Luis Martínez-Sobrido
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

8.  RNA virus building blocks-miRNAs not included.

Authors:  Lauren C Aguado; Benjamin tenOever
Journal:  PLoS Pathog       Date:  2018-05-31       Impact factor: 6.823

9.  Long-term expression of miRNA for RNA interference using a novel vector system based on a negative-strand RNA virus.

Authors:  Tomoyuki Honda; Yusuke Yamamoto; Takuji Daito; Yusuke Matsumoto; Akiko Makino; Keizo Tomonaga
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.